OneSource Specialty Pharma Limited, India’s pioneering specialty pharma pure-play CDMO (Contract Development and Manufacturing Organization) and an associate company of Strides, has announced a strategic partnership with Bhami’s Research Laboratory (BRL). This collaboration grants OneSource access to BRL’s revolutionary HILOPRO® formulation technology, enabling the subcutaneous delivery of high-concentration biologic therapies. This innovative approach is set to transform the administration of biologics, including monoclonal antibodies and fusion proteins, by reducing viscosity and simplifying the delivery process.

OneSource, renowned for its capabilities in biologics, complex injectables, drug-device combination products, and soft gelatin capsules, operates five state-of-the-art cGMP facilities. The company has an impeccable compliance record, with successful inspections from major health agencies, including the USFDA and EU authorities. This agreement will allow OneSource to integrate BRL’s advanced formulation technology into its development and manufacturing services, enhancing its offerings across drug products and substances.

Neeraj Sharma, Managing Director of OneSource, expressed enthusiasm about the partnership, stating, “Our collaboration with Bhami’s Research Laboratory marks a significant milestone in enhancing the subcutaneous delivery of high-concentration biologic therapies. The adoption of this technology not only addresses critical challenges in biopharmaceutical development but also offers substantial benefits, such as improved healthcare accessibility and reduced treatment costs. This aligns perfectly with our commitment to leveraging innovative solutions to improve patient outcomes.”

Also Read: DGHS Sparks Health Revolution: India’s Medical Leaders Unite for Prevention-First Approach and Tobacco Control

Dr. Surya Pai, Co-founder and CEO of BRL, also commented on the collaboration, highlighting the potential of their globally patented high-concentration, low-viscosity protein drug delivery platform. He said, “Partnering with OneSource, a distinguished player in the specialty pharma CDMO sector, enables us to expand the reach of our advanced subcutaneous protein delivery platform. Together, we are poised to set new benchmarks in biopharmaceutical innovation and enhance healthcare outcomes globally.”

Together, OneSource and Bhami’s Research Laboratory are paving the way for a new era in biologics, enhancing patient care and accessibility worldwide.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!